Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further...
Josh Brown notices a "massive multi-year breakout" in biotech stocks (IBB +0.9%), with further gains likely as large pharmas continue to acquire the smaller firms so long as their own R&D departments are starving. "They have tons of cash and a burning desire to add pipeline - which makes almost every publicly-traded biotech a target for someone."
From other sites
Video at CNBC.com (Thu, 5:35PM)
Video at CNBC.com (Tue, 6:49AM)
Video at CNBC.com (Feb 4, 2016)
Video at CNBC.com (Feb 2, 2016)
Video at CNBC.com (Dec 3, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs